BioArctic AB (publ) (BRCTF)
OTCMKTS
· Delayed Price · Currency is USD
20.78
+2.04 (10.87%)
Jun 13, 2025, 10:19 AM EDT
BioArctic AB Revenue
BioArctic AB had revenue of 1.29B SEK in the quarter ending March 31, 2025, with 4,251.06% growth. This brings the company's revenue in the last twelve months to 1.52B, up 501.62% year-over-year. In the year 2024, BioArctic AB had annual revenue of 257.35M, down -58.22%.
Revenue (ttm)
1.52B SEK
Revenue Growth
+501.62%
P/S Ratio
12.25
Revenue / Employee
14.18M SEK
Employees
107
Market Cap
1.85B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.35M | -358.64M | -58.22% |
Dec 31, 2023 | 616.00M | 386.56M | 168.49% |
Dec 31, 2022 | 229.43M | 203.77M | 794.02% |
Dec 31, 2021 | 25.66M | -39.54M | -60.64% |
Dec 31, 2020 | 65.21M | -217.74M | -76.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
BioArctic AB News
- 11 days ago - BioArctic's Capital Markets Day 2025 - entering a new era of growth - PRNewsWire
- 4 weeks ago - Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) - PRNewsWire
- 4 weeks ago - Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET - PRNewsWire
- 5 weeks ago - Exidavnemab phase 2a study expanded to include MSA patients - PRNewsWire
- 2 months ago - The European Commission refers lecanemab decision to Appeal Committee - PRNewsWire
- 2 months ago - BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference - PRNewsWire
- 3 months ago - BioArctic receives Orphan Drug Designation for exidavnemab the US - PRNewsWire
- 3 months ago - Therapeutic Goods Administration decides not to register lecanemab in Australia - PRNewsWire